Pharmaceuticals, Biotechnology and Life Sciences
GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…
SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company…
WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and…
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) — Immunovant (Nasdaq: IMVT) today announced that it will report…
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today…
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it…
RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) — XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today…
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine…
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…